Skip to main content
Premium Trial:

Request an Annual Quote

Sebia M-inSight

Sebia has launched its serum-based minimal residual disease (MRD) test for patient monitoring in multiple myeloma. M-inSight is a laboratory-developed test being offered by Corgenix, a CAP-accredited, CLIA-licensed laboratory, which is part of the Sebia Group. The personalized, targeted mass spectrometry test uses clonotypic peptides mass spectrometry to sensitively detect the monoclonal protein secreted by the patient's tumor cells in serum. The company said M-inSight was developed in partnership with Erasmus Medical Center and Radboud University Medical Center in The Netherlands.